Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
about
The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in childrenDid FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend AnalysisEvaluation of Off-label Prescribing at a Children's Rehabilitation Center.Nocebo effect in randomized clinical trials of antidepressants in children and adolescents: systematic review and meta-analysis.Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data.Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications.Temporal trends in antidepressant prescribing to children in UK primary care, 2000-2015.Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events.Trends in antidepressant prescribing to children and adolescents in Canadian primary care: A time-series analysis.Trends in Off-Label Prescribing of Sedatives, Hypnotics and Antidepressants among Children and Adolescents - A Danish, Nationwide Register-Based Study.Protecting Children Through Research.Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec.Unlicensed and off-label use of drugs in pediatric surgical units at tertiary care hospitals of Pakistan.Off-label prescribing of psychotropic drugs in a Danish child and adolescent psychiatric outpatient clinic.
P2860
Q28537908-B5C90813-EF77-4463-9145-D115C1CD7395Q28551085-EB61EF29-D0AA-46E5-8F2C-760F75EB1DEFQ30300386-D8469EB2-62CF-4186-B498-4D3BFA9645A6Q30596803-02D783D5-3DEC-4B0E-8585-651CDFC43C7EQ31021577-73894073-D8A8-4C20-8152-A022C1CCA001Q31049668-5470697C-4279-4FEA-8051-328F7FEF2457Q33763721-5A4D1FAE-BC57-4E7C-A4E0-F8F76E38FFFAQ37248061-F94911D1-D93D-4BE2-AD5A-EA5B0987C12BQ38086176-74F90745-F099-47F8-B1BC-8352639C516DQ38736791-9842BC31-3D87-4AA0-9F32-9A68AC5E01F4Q39012514-416FE95B-9341-43F5-A61F-8C58CAF845D8Q40430227-D37E7CEC-788F-4B4A-BD1A-EFC171E02A49Q41869915-165A0908-5AD3-46D5-B3BF-919610D1F381Q47315634-5EB4CF58-DED7-45B2-9D0F-102ACFC85BE2Q50565390-20A626F3-E66C-44BF-BECA-C34D45875AEF
P2860
Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Off-label antidepressant use i ...... extent and level of evidence.
@en
Off-label antidepressant use i ...... extent and level of evidence.
@nl
type
label
Off-label antidepressant use i ...... extent and level of evidence.
@en
Off-label antidepressant use i ...... extent and level of evidence.
@nl
prefLabel
Off-label antidepressant use i ...... extent and level of evidence.
@en
Off-label antidepressant use i ...... extent and level of evidence.
@nl
P2860
P356
P1476
Off-label antidepressant use i ...... extent and level of evidence.
@en
P2093
Angela S Czaja
Robert Valuck
P2860
P304
P356
10.1002/PDS.3312
P577
2012-07-04T00:00:00Z